StockAnalyzer

Financial Analysis

DashboardSectorsComparablesScreenerUniverseMicrocapsAI 2nd OrderTheme MapEnergy & MaterialsMacroWatchlistCompareMi CarteraPortfolio

Recent

v0.1
1231.TW$86.10+0.12%
Fair $86.10+0.0%

1231.TW

Lian Hwa Foods Corporation

Consumer Defensive / Packaged FoodsTaiwan

$86.10

+0.10 (+0.12%)

Fairly Valued+0.0%Fair Value $86.10Fund rank 23/100 · Data gapFallback financials|
SA 34/D
F-Score: 4/9

FCF base 3Y

n/d

n/d CAGR · yield n/d

FCF base 5Y

n/d

n/d base · n/d expected

Precio de entrada

n/d

MOS 34% · confianza 16%

FCF escenarios

weak_data · normalized FCF $-327.8M · quality 36.0/100

Data gap 23/100
Bear 5Yn/dn/d
Base 5Yn/dn/d
Bull 5Yn/dn/d
Return 0/100Downside 20/100Model quality 13/100Data QA 20/100

Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.

Quality + valuation scorecard

SA Score

34/100

D

Piotroski

4/9

balance/quality

Valuation

50/100

+0.0% upside

5Y CAGR

+0.0%

50/100

Data QA

16/100

SEC 0%

Latest source: unknownPeriods: 4Warnings: 0unknown: 4
No SEC-backed annual rows; valuation uses fallback financial data. Insufficient audited annual history (<3 SEC-backed years); composite fair value and forward targets are disabled until manually verified.
Thesis & Journal · 1231.TWLocal privado en este navegador · Lian Hwa Foods Corporation
Plantilla tipo buy-side: tesis, bull/base/bear, catalizadores, riesgos, kill criteria y fecha de revisión. Esto no gasta GPT-5.5; luego lo usamos como contexto del memo.

Sin guardar todavía.

Market Cap

$25.7B

P/E

22.6x

↑

EV/EBITDA

16.7x

↑

ROE

15.7%

↑

Gross Margin

20.4%

↓

Debt/Equity

0.74

↑
52-Week Range$86
$81$141

TradingView lightweight chart

1231.TW price, volumen y niveles de valoración

Último $86.10Periodo +453.1%
Fair value: $86.10

Price & Ratios

Absolute Values (Left Axis)

Ratios / Percentages (Right Axis)

Financial statement dashboard

Crecimiento, márgenes y provenance

2022–2025 · 3 años de histórico normalizado

Revenue CAGR

+6.1%

FCF CAGR

—

FCF margin

1.5%

FCF / Net income

0.17x

Latest source

Provider fallback

Margin decomposition

Último año: revenue $12.87B · net income $1.14B · FCF $196.4M

2022-FY → 2025-FY

Gross margin

20.4%-2.8% pts

Operating margin

8.9%-2.1% pts

Net margin

8.8%+0.8% pts

FCF margin

1.5%+4.7% pts
MetricTTM
2025
2024
2023
2022
Income Statement
Revenue$12.87B$12.87B$12.20B$10.85B$10.77B
Net Income$1.14B$1.14B$1.15B$969.6M$871.8M
EBITDA$1.83B$1.83B$1.84B$1.53B$1.39B
EPS——3.843.252.92
Gross Margin20.4%20.4%20.8%21.0%23.2%
Operating Margin8.9%8.9%8.5%8.4%10.9%
Net Margin8.8%8.8%9.4%8.9%8.1%
Balance Sheet
Debt/Equity0.740.740.800.820.64
Current Ratio1.421.42———
Cash Flow
Free Cash Flow$196.4M$196.4M$-327.8M$-374.8M$-344.1M
Returns
ROE15.7%15.7%17.5%16.8%16.9%
Valuation
P/E22.6022.6034.3322.2118.95
EV/EBITDA16.7116.7123.9116.5314.02
P/B3.543.546.023.743.21
Growth & Yield
Revenue Growth5.5%5.5%12.4%0.7%—
EPS Growth——18.3%11.2%—
Dividend Yield1.9%1.9%———

Revenue, Net Income & Free Cash Flow ($B)

Margins (%)

Returns (%)

Leverage & Liquidity

Reverse DCF · market-implied EPS growthterminal P/E 15.0x · COE 10.0%
Reverse DCF requires positive EPS; loss-making or zero-EPS companies cannot produce a clean EPS hurdle.

Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.

Return attribution · 1Y approxreconcilia total -30.0%

Total return

-30.0%

Start / end P/E

n/dx → n/dx

EPS bridge

3.84 → n/d

Residual

-31.9%

EPS growthn/d
Multiple reratingn/d
Dividend+1.9%
Residual / FX / buybacks / cross-term-31.9%

EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.

Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.